Dr. Reddy's Launches Generic Olopatadine HCl Ophthalmic Solution OTC in US
Dr. Reddy's Laboratories launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), a generic equivalent of Extra-Strength Pataday® Once-Daily Relief, in the U.S. This expands their OTC eye-care portfolio. The Pataday® brand had U.S. sales of approximately $69.9 million (₹582.7 crore) in the latest 52-week period.
The launch of a generic equivalent of a product with significant sales ($69.9 million) could have a moderate impact on Dr. Reddy's revenue and market share in the OTC eye-care segment.
The launch of a new generic product, especially a first-to-market one, is generally positive for a pharmaceutical company as it expands its market reach and revenue streams.
Dr. Reddy's Laboratories announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the U.S. market. This product is the generic equivalent of Extra-Strength Pataday® Once-Daily Relief and has been approved by the U.S. Food and Drug Administration (USFDA).
The Antihistamine eye drop is indicated for the temporary relief of itchy eyes caused by allergens like pollen, ragweed, grass, and animal hair and dander. This launch expands Dr. Reddy's existing OTC eye-care portfolio, which already includes Olopatadine Hydrochloride Ophthalmic Solution USP in 0.2% and 0.1% strengths.
Milan Kalawadia, CEO of North America Generics at Dr. Reddy's Laboratories, Inc., highlighted that this first-to-market launch demonstrates the company's capabilities in bringing store-brand equivalents of OTC brands to the U.S. market. Dr. Reddy's aims to deepen its collaboration with retail customers through this new offering.
The Pataday® brand generated approximately $69.9 million (approximately ₹582.7 crore) in U.S. sales for the 52 weeks ending December 27, 2025. Dr. Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is available in a 2.5 mL bottle.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.